Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Sumitomo Offloads Entire Stake in Roivant as Earnings Tank
Amid deteriorating earnings, Sumitomo Pharma is returning its entire stake in Roivant Sciences back to the UK-based company for US$648 million, or around 98 billion yen, with the transaction scheduled for early this month. In its statement on April 2,…
To read the full story
Related Article
- Sumitomo Ups FY2025 Forecast on North America-Driven Profit Growth
November 4, 2025
- Sumitomo Pharma Rejoins PhRMA amid US Tariff Concerns, Posts H1 Forecasts
August 1, 2025
- Sumitomo Pharma Logs 1st Operating Profit in 3 Years in FY2024
May 14, 2025
- Sumitomo Ups FY2024 Earnings Outlook, Now Expects Black Ink
February 3, 2025
- Sumitomo’s FY2024 1H Results Meet Initial Plan amid Restructuring
October 31, 2024
- Sumitomo Sales Surge 18% in April-September on 3 Key Brands
October 31, 2024
- As Latuda Sales Evaporate, Sumitomo Shakes Up Top Brass for Turnaround
May 15, 2024
- Sumitomo to Cut Med- to Long-Term Guidance amid Tepid Uptake of New Drivers
February 1, 2024
- Sumitomo Eyes Return to Core Operating Profit in FY2024, Pruning Roivant Shares
November 1, 2023
BUSINESS
- Lenvima-Keytruda Triplets Fail in First-Line RCC Trial
April 22, 2026
- Another Global PIII Shuttered for Arcus-Partnered TIGIT Combo: Taiho
April 22, 2026
- Imdelltra Likely to Gain Ground in 2nd-Line SCLC after Label Update: Oncologist
April 22, 2026
- Jazz, Nippon Zoki Ink Deal to Bring Cannabis-Derived Epilepsy Drug to Japan
April 22, 2026
- Padcev-Keytruda Gets FDA Priority Review for Cisplatin-Eligible Perioperative MIBC
April 22, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…